1
|
Rapp J, Ness J, Wolf J, Hospach A, Liang P, Hug MJ, Agostini H, Schlunck G, Lange C, Bucher F. 2D and 3D in vitro angiogenesis assays highlight different aspects of angiogenesis. Biochim Biophys Acta Mol Basis Dis 2024; 1870:167028. [PMID: 38244944 DOI: 10.1016/j.bbadis.2024.167028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Revised: 01/12/2024] [Accepted: 01/13/2024] [Indexed: 01/22/2024]
Abstract
In angiogenesis research, scientists need to carefully select appropriate in vitro models to test their hypotheses to minimize the risk for false negative or false positive study results. In this study, we investigate molecular differences between simple two-dimensional and more complex three-dimensional angiogenesis assays and compare them to in vivo data from cancer-associated angiogenesis using an unbiased transcriptomic analysis. Human umbilical vein endothelial cells were treated with VEGF in 2D wound healing and proliferation assays and the 3D spheroid sprouting assay. VEGF-induced transcriptomic shifts were assessed in both settings by bulk RNA sequencing. Immunocytochemistry was used for protein detection. The data was linked to the transcriptomic profile of vascular endothelial cells from a single cell RNA sequencing dataset of various cancer tissue compared to adjacent healthy tissue control. VEGF induced a more diverse transcriptomic shift in vascular endothelial cells in a 3D experimental setting (767 differentially expressed genes) compared to the 2D settings (167 differentially expressed genes). Particularly, VEGF-induced changes in cell-matrix interaction, tip cell formation, and glycolysis were pronounced in the 3D spheroid sprouting experiments. Immunocytochemistry for VCAM1 and CD34 confirmed enhanced expression in response to VEGF-treatment in 3D settings. In vivo, vascular endothelial cells within various cancer tissue were characterized by strong transcriptomic changes in cell-matrix interaction and glycolysis similar to the 3D setting. Consequently, 3D assays may better address certain key aspects of angiogenesis in comparison to fast and scalable 2D assays. This should be taken into consideration within the context of each research question.
Collapse
Affiliation(s)
- Julian Rapp
- Eye Center, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
| | - Jan Ness
- Eye Center, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany; Institute of Pharmaceutical Sciences, Faculty of Chemistry and Pharmacy, University of Freiburg, Freiburg, Germany
| | - Julian Wolf
- Eye Center, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
| | - Alban Hospach
- Eye Center, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
| | - Paula Liang
- Eye Center, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
| | - Martin J Hug
- Pharmacy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
| | - Hansjürgen Agostini
- Eye Center, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
| | - Günther Schlunck
- Eye Center, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
| | - Clemens Lange
- Eye Center, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany; Ophtha-Lab, Department of Ophthalmology, St. Franziskus Hospital Muenster, Muenster, Germany
| | - Felicitas Bucher
- Eye Center, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany.
| |
Collapse
|
2
|
Rapp J, Hospach A, Liang P, Schwämmle M, Renz L, Agostini H, Schlunck G, Bucher F. Oncostatin M Reduces Pathological Neovascularization in the Retina Through Müller Cell Activation. Invest Ophthalmol Vis Sci 2024; 65:22. [PMID: 38190125 PMCID: PMC10777876 DOI: 10.1167/iovs.65.1.22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2023] [Accepted: 12/01/2023] [Indexed: 01/09/2024] Open
Abstract
Purpose Continuous vision loss due to vasoproliferative eye disease still represents an unsolved issue despite anti-vascular endothelial growth factor (VEGF) therapy. The impact of signal transducer and activator of transcription 3 (STAT3) signaling on retinal angiogenesis and its potential use as a therapeutic target remain controversial. In vitro, oncostatin M (OSM), as a strong STAT3 activator, possesses robust proangiogenic activity. This study investigated to what extent the proangiogenic effects of OSM translate to the in vivo setting of vasoproliferative eye disease. Methods The in vitro effect of OSM on endothelial cells was investigated in the spheroid sprouting assay and through RNA sequencing. The mouse model for oxygen-induced retinopathy (OIR) was used to evaluate the impact of OSM in vivo. Signaling patterns were measured by western blot and retinal cryosections. Primary Müller cell cultures were used to evaluate the effect of OSM on the Müller cell secretome. Murine retinal vascular endothelial cells were isolated from OIR retinas using fluorescence-activated cell sorting (FACS) and were used for RNA sequencing. Results Although OSM induced pro-angiogenic responses in vitro, in the OIR model intravitreal injection of OSM reduced retinal neovascularization by 65.2% and vaso-obliteration by 45.5% in Müller cells. Injecting OSM into the vitreous activated the STAT3 signaling pathway in multiple retinal cell types, including Müller cells. In vitro, OSM treatment increased CXCL10 secretion. RNA sequencing of sorted vascular endothelial cells at OIR P17 following OSM treatment indicated downregulation of angiogenesis- and mitosis-associated genes. Conclusions In vivo, OSM reveals a beneficial angiomodulatory effect by activating Müller cells and changing their secretome. The data highlight contradictions between cytokine-induced effects in vitro and in vivo depending on the cell types mediating the effect.
Collapse
Affiliation(s)
- Julian Rapp
- Eye Center, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Alban Hospach
- Eye Center, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Paula Liang
- Eye Center, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Melanie Schwämmle
- Eye Center, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
- Faculty of Biology, University of Freiburg, Freiburg, Germany
| | - Lisa Renz
- Eye Center, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Hansjürgen Agostini
- Eye Center, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Günther Schlunck
- Eye Center, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Felicitas Bucher
- Eye Center, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| |
Collapse
|
3
|
Foeldvari I, Minden K, Ganser G, Haas JP, Hospach A, Huppertz HI, Horneff G. Zehn Jahre Erfahrung im deutschen JIA-Etanercept-Register. ACTA ACUST UNITED AC 2017. [DOI: 10.1055/s-0037-1618085] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Zusammenfassung
Hintergrund: Seit Einführung der TNF-Inhibitoren in die Therapie der juvenilen idiopathischen Arthritis (JIA) hat sich die Prognose für viele Patienten erheblich verbessert.
Ziele und Methoden: Daten des deutschen JIA-Etanercept-Registers wurden in Jahreskohorten von 2000–2010 bzgl. Patientencharakteristika, Vorbehandlung, Begleittherapie und Krankheitsaktivität analysiert. Die Wirksamkeit der Therapie wurde anhand der PedACR30/50/70-Kriterien und Kriterien für inaktive Erkrankung und Remission analysiert. Sicherheitsbewertungen erfolgten auf der Basis von Berichten über unerwünschte Ereignisse.
Ergebnisse: Von 2000 bis 2010 wurden 1335 mit Etanercept behandelte JIA-Patienten in das Register aufgenommen. Am häufigsten erhielten Patienten mit einer seronegativen Polyarthritis Etanercept. In den frühen Jahreskohorten lag der Anteil von Patienten mit einer systemischen JIA bei 26 %, zuletzt zwischen zwei und fünf Prozent. Demgegenüber stieg der Anteil von Patienten mit einer Enthesitis-assoziierten Arthritis von zwei Prozent auf 17 % an. Die initial aufgenommenen Patienten wurden zuvor mit zahlreichen Antirheumatika (Mittel 3,4) einschließlich Zytostatika vorbehandelt. Diese Anzahl reduzierte sich über die Jahre auf 1,3/Patient. In der initialen Patientenkohorte wurden Kortikosteroide bei 83 %, Methotrexat bei 95 % und andere DMARDs bei 45 % der Patienten begleitend eingesetzt. Diese Begleitmedikation verminderte sich bei der Patientenkohorte mit Behandlungsbeginn in 2010 auf 27 %, 67 % und zehn Prozent. Die mittlere Krankheitsdauer vor Behandlungsbeginn nahm von 6,1 Jahren (Median 4,5 Jahre) auf 3,4 Jahre (Median 1,9 Jahre) ab. Der Anteil der Patienten mit einem PedACR70-Score nach Abschluss der ersten zwölf Behandlungsmonate stieg von 57 % auf 74 % an. Eine inaktive Erkrankung innerhalb eines Jahres wurde bei 24 % der initialen Patientenkohorte dokumentiert, während sich diese Rate im Beobachtungsverlauf auf 54 % erhöhte. Die Gesamtzahl unerwünschter Ereignisse im ersten Jahr der Behandlung war konstant, während die Rate schwerwiegender unerwünschter Ereignisse von 0,13/Patient auf 0,02/Patient sank.
Fazit: Bei JIA-Patienten wird eine Therapie mit Etanercept zunehmend früher begonnen. Es erfolgen weniger Vorbehandlungen und es werden weniger Medikamente begleitend eingesetzt. Dabei zeigt sich eine verbesserte Verträglichkeit mit weniger ernsthaften Nebenwirkungen und eine höhere Effektivität.
Collapse
|
4
|
Horneff G, Schultz A, Hospach A, Ganser G, Foeldvari I, Thon A, Trauzeddel R, Weller F, Minden K, Haas J. OP0216 Safety of Tocilizumab, Interleukin-1 Inhibitors and Etanercept in 262 Systemic Juvenile Idiopathic Arthritis Patients: Table 1. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.2069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
5
|
Horneff G, Schultz A, Hospach A, Ganser G, Foeldvari I, Thon A, Trauzeddel R, Weller F, Minden K, Haas J. THU0228 Efficacy Comparison with Tocilizumab, Interleukin-1 Inhibitors and Etanercept for Treatment of Systemic Juvenile Idiopathic Arthritis:. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.2986] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
6
|
Horneff G, Klein A, Hospach A, Oommen P, Foeldvari I, Kuemmerle-Deschner J, Feddersen I, Minden K. OP0219 Update on Malignancies in Children with Juvenile Idiopathic Arthritis in The German Biker Registry: Table 1. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.2755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
7
|
Horneff G, Huppertz I, Haas P, Minden K, Ganser G, Hospach A, Trauzeddel R. Safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2015. [PMCID: PMC4598880 DOI: 10.1186/1546-0096-13-s1-p165] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
8
|
Niewerth M, Kallinich T, Hospach A, Behrendes R, Thon A, Minden K. Impact of hereditary periodic fever syndromes and its change over time. Pediatr Rheumatol Online J 2015. [PMCID: PMC4599683 DOI: 10.1186/1546-0096-13-s1-p46] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
9
|
Niewerth M, Klotsche J, Liedmann I, Hospach A, Horneff G, Thon A, Huppertz HI, Kümmerle-Deschner J, Sengler C, Minden K. AB1002 Disease Characteristics and Disease Activity in Enthesitis-Related Arthritis During the First Year of Rheumatology Care – Results from an Inception Cohort Study. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.5114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
10
|
Jansson A, Borte M, Hospach A, Kallinich T, Oommen P, Trauzeddel R, Weißbarth-Riedel E, Windschall D, Girschick H, Grote V. Diagnostik und Therapie der nichtbakteriellen Osteitis. Monatsschr Kinderheilkd 2014. [DOI: 10.1007/s00112-014-3148-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
11
|
Niewerth M, Klotsche J, Foeldvari I, Ganser G, Hospach A, Zink A, Minden K. AB0906 Physical Activity in Adolescents with Juvenile Idiopathic Arthritis. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
12
|
Horneff G, Von Stackelberg S, Foeldvari I, Haas J, Ganser G, Minden K, Hospach A. OP0183 Jadas Remission and Minimal Disease Activity upon First Biologic in Jia:. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
13
|
Storms M, Klotsche J, Liedmann I, Niewerth M, Thon A, Ganser G, Haas JP, Hospach A, Minden K. FRI0548 Costs of Early Juvenile Idiopathic Arthritis (JIA). Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.5056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
14
|
Horneff G, Onken N, Hospach A, Ganser G, Huppertz HI. SAT0462 Experience with Tocilizumab in 29 Patients with Systemic Onset Juvenile Idiopathic Arthritis. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2013-eular.2186] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
15
|
Abstract
Acute otitis media is one of the most common infections in childhood and the options of therapy have been examined in numerous studies. Nevertheless, there are controversial opinions regarding the question whether antibiotic therapy makes sense. This is proved through the many different ways that the primary treatment of the middle ear infection is handled throughout the international community. This work gives an overview of the current knowledge and based on these results gives practical recommendations to assist with the diagnosis and treatment of the individual patients.
Collapse
Affiliation(s)
- P Amrhein
- Klinikum Stuttgart, Klinik für Hals-, Nasen-, Ohrenkrankheiten, Plastische Operationen, Abteilung für pädiatrische HNO-Heilkunde und Otologie, Klinikum Stuttgart, Bismarckstr. 8, 70176, Stuttgart, Deutschland.
| | | | | | | |
Collapse
|
16
|
Raab A, Minden K, Niewerth M, Klotsche J, Geisemeyer N, Sengler C, Zink A, Ganser G, Hospach A, Trauzeddel R. SAT0449 Three-Year Outcome of Children with Systemic-Onset Juvenile Idiopathic Arthritis: Longitudinal Data from the German National Paediatric Rheumatologic Database. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.2173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|